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ABSTRACT Patients with chronic obstructive pulmonary disease (COPD) commonly present with
multimorbidity. We aimed to investigate the association between COPD and the development of
peripheral arterial disease (PAD) in the general population, and how this might affect mortality among
individuals with COPD.
We included 3123 participants of the population-based Rotterdam Study without PAD at baseline
(mean age 65 years; 57.4% female). The association between COPD at baseline and PAD during follow-up
was studied using logistic regression (PAD being indicated by an ankle–brachial index (ABI) of 0.9 or
less). Cox regression was used for mortality analysis and interaction terms were used to investigate
mortality risk modification by PAD.
The presence of COPD was associated with incident PAD (adjusted odds ratio 1.9, 95% CI 1.1–3.2).
Mortality rates per 100000 person-years were as follows: 10.0 in individuals without COPD or PAD, 18.4
in those with COPD only, 16.1 in those with PAD only and 30.1 in individuals with both COPD and
PAD. No statistical interaction was found between PAD and COPD on risk of dying.
Individuals with COPD have an almost doubled risk of developing PAD. Although PAD does not
modify the association between COPD and mortality, people suffering from both diseases have
substantially higher mortality rates.
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Individuals with COPD have an almost doubled risk of developing peripheral arterial disease
(PAD). People suffering from both COPD and PAD have substantially higher mortality rates.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the third major cause of death worldwide [1]. Beyond
airflow limitation and respiratory impairment, COPD patients often suffer from multimorbidities, the most
prominent of which are vascular diseases [2, 3].
Atherosclerosis is known as a major cause of symptomatic vascular disease. One of the manifestations of
atherosclerosis is peripheral arterial disease (PAD), which refers to the occlusion of the arteries in the
lower limbs. PAD is often asymptomatic but can be present in advanced stages in the form of intermittent
claudication, leg pain at rest and, rarely, non-healing wounds, ulcerations and gangrene [4]. Patients with
PAD have comparable but not identical risk factor profiles to patients with coronary heart disease, with
systemic inflammation, diabetes and smoking being the predominant risks in PAD [5–8].
The prevalence of PAD in individuals with COPD shows a wide range of variation depending on the
severity of COPD in the study population. Its prevalence was found to be 8% in Asian COPD patients,
8.8% in the German COSYCONET study of COPD patients followed in secondary care and 36.8% in
COPD patients hospitalised for a severe exacerbation [9–11].
A previous study by PECCI et al. [10] demonstrated that PAD was asymptomatic in a large proportion of
COPD patients and was associated with more severe lung disease than in COPD subjects without PAD.
Therefore, longitudinal studies investigating the association between COPD and incident PAD are needed
[12]. In addition, although PAD is known to have a significant impact on mortality, it is unknown
whether the risk of mortality is higher in patients with both COPD and PAD. Therefore, the objectives of
our study were as follows: 1) to investigate the association between COPD and incident PAD in a
longitudinal cohort, and 2) to elucidate the effect of PAD on mortality in subjects with COPD in a
community-dwelling population of middle-aged and older subjects.
Methods
Setting
The present study was embedded within the Rotterdam Study, an ongoing prospective population-based
cohort which was enroled to investigate the occurrence of, as well as risk factors for, chronic diseases in
the general population. The aims and methods of the Rotterdam Study have previously been published in
detail [13]. In short, the Rotterdam Study started in 1990, with inhabitants of the Ommoord district of
Rotterdam being invited to the research centre for follow-up examination every 3–4 years. Participants
were additionally monitored continuously for morbidity and mortality through linkage of both general
practitioner (GP) and municipality records to the study. The present study was conducted using data from
the first cohort of the Rotterdam Study (RS-I) and comprises two parts. The first longitudinal analysis was
performed in order to study the association between COPD (measured at baseline, between 1990 and
1993) and newly diagnosed PAD (measured between 1996 and 2000) (figure 1). The second analysis
aimed to investigate the effect of PAD on mortality in subjects with COPD (measured between 1996 and
2016). The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC
(registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population
Screening Act WBO, license number 1071272–159521-PG). All participants provided written informed
consent to participate in the study and to have their information obtained from treating physicians.
COPD diagnosis
We validated whether participants had COPD by reviewing the medical charts, including outpatient clinic
reports and hospital discharge letters, of all those who used medication for obstructive lung disease for at
least 6 months (anatomical therapeutic chemical (ATC) classification code R03) or who stated they had
COPD in a questionnaire. COPD cases were defined as having a medical COPD diagnosis supported by
clinical presentation and/or obstructive lung function [14]. The index date was defined as the date of
diagnosis of COPD as described in the medical charts or the date of the first prescription for COPD
medication in patients with COPD, whichever came first. In this study COPD data was used at baseline for
the first objective and at follow-up for the second objective.
Assessment of PAD
The method of measuring the ankle–brachial index (ABI) has been described previously [15]. In short,
blood pressure (BP) in the arm (systolic BP) was determined by calculating the mean of two successive
measurements at the right brachial artery while the participant was in a sitting position (using a
random-zero sphygmomanometer) [15]. In addition, the systolic BP of the posterior tibial artery was
measured in both the left leg and the right leg while the participant was in a supine position (using a
random-zero sphygmomanometer and an 8-MHz continuous-wave Doppler probe (Huntleigh 500 D,
Huntleigh Technology)). The ABI was defined as the ratio of systolic BP at the ankle to systolic BP at the
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arm and was calculated for each leg. The presence of PAD was defined as an ABI of 0.90 or less in at least
one leg [5]. Patients with prevalent PAD at baseline were excluded and only newly diagnosed (incident)
PAD during follow-up was considered as an outcome. Severe PAD was defined as an ABI of less than 0.6
[11]. Besides the ABI measurements, we used the criteria of the World Health Organization (WHO)/Rose
questionnaire, which was incorporated in the home interview [16], to investigate intermittent claudication
and capture symptomatic PAD.
Follow-up for mortality
To investigate whether PAD increases the risk of all-cause mortality in subjects with or without COPD,
3123 individuals with two ABI measurements were followed from the second PAD measurement until
mortality, or until the last visit to the study centre.
Information on mortality was obtained from the municipality of Rotterdam and was additionally validated
with data from study participants medical records, as kept by their GPs and as described in detail
previously [17]. Mortality data was complete until August 2016.
Covariables
Relevant covariables at baseline were obtained for each analysis using interview, blood sampling and
physical examination [18]. Smoking status was assessed by interview and categorised as never, former or
current smoker, or as ever or never smoker. Body mass index (BMI) was calculated by dividing body
weight (in kg) by height (in m2). Hypertension was defined as a systolic BP ⩾140 mmHg, a diastolic BP
⩾90 mmHg, or the use of BP-lowering drugs. Subjects were classified as statin users if they had received at
least one prescription for statins at baseline. Information on statin use was obtained from interview and
from pharmacies. Type-2 diabetes mellitus was defined, in accordance with recent WHO guidelines, by
fasting blood glucose ⩾7.0 mmol·L−1, non-fasting blood glucose ⩾11.1 mmol·L−1 (in the absence of fasting
samples), or the use of blood glucose lowering medication [17]. Concentrations of high-density lipoprotein
16.5 years
7 years
Baseline measurement (RS-I-1; 1990-1993)
Total subjects (n=7983)
No ABI measurements (n=1533)
Baseline measurement (RS-I-1; 1990-1993)
ABI measurement at baseline (n=6450)
Follow-up measurement (RS-I-3; 1996-2000)
Two consecutive measurements of ABI
excluding prevalent PAD (n=3123)
No PAD (n=2676)
COPD without PAD (n=198)
Non-COPD without PAD (n=2478)
Newly diagnosed PAD (n=447)
COPD with PAD (n=51)
Non-COPD with PAD (n=396)
Prevalent PAD (n=336)
Died (n=1881)
Only one measurement of PAD (n=1110)
End of follow-up for mortality (2016)
Mortality rates per 100000 person-years
Non-COPD without PAD: 10.0
PAD only: 16.1
COPD only: 18.4
COPD and PAD: 30.1
FIGURE 1 Flow chart to investigate the association between chronic obstructive pulmonary disease (COPD)
and newly diagnosed peripheral arterial disease (PAD). ABI: ankle–brachial index; RS-I-1: the first visit of the
first cohort of the Rotterdam Study; RS-I-3: the third visit of the first cohort of the Rotterdam Study.
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(HDL) cholesterol and total cholesterol were measured from blood samples using an automated enzymatic
method [19]. The HDL cholesterol/total cholesterol ratio was calculated by dividing HDL blood
concentrations by total cholesterol concentrations. Ethnicity was based on genetic ancestry data or
interview data in the absence of genetic information. High-sensitivity C-reactive protein (hs-CRP) was
measured using rate near infrared particle immunoassay (Immage Immunochemistry System, Beckman
Coulter, Fullerton, CA, USA).
Statistical analysis
To study population characteristics the Chi-squared test and the independent sample t-test were used to
test differences between individuals with or without COPD. We determined the association between
baseline COPD and the development of PAD (assessed during a follow-up visit), using logistic regression
after exclusion of individuals with prevalent PAD at baseline. For the association between COPD and
newly diagnosed PAD, we adjusted for covariables that were considered risk factors for atherosclerosis and
cardiovascular disease. The following potential confounders were considered: age, sex, smoking status,
smoking duration in pack-years, BMI, hypertension, hs-CRP, statin use, HDL/cholesterol ratio, ethnicity
and diabetes mellitus. Missing data on covariables were imputed using the expectation maximization
method and effect modification was tested with interaction terms. Additional sensitivity analyses were
performed by adjusting for hs-CRP (as a marker for inflammation) and by excluding individuals with
incident COPD or individuals with an ABI greater than 1.4 (as a marker for arterial stiffening [15]) from
the analysis.
As a secondary objective, we aimed to study the impact of PAD on the risk of mortality among individuals
with COPD. For this analysis four groups were defined as follows (all assessed at the second PAD round):
1) individuals without COPD and without PAD, 2) individuals with COPD only, 3) individuals with PAD
only, and 4) individuals with both COPD and PAD. Mortality rates were obtained by dividing the number
of deaths by the total number of person-years of subjects at risk and were presented per 100000
person-years. Confidence intervals around these rates were calculated using a Poisson distribution.
Follow-up time for all subjects was defined as the time period between the start of the second analysis
(where incident PAD was measured) and death or the last visit to the study centre. Sensitivity analysis was
performed by censoring for incident COPD during follow-up. Median follow-up time was estimated using
the reverse Kaplan–Meier method. Crude survival curves were obtained using the Kaplan–Meier survival
method. The Cox proportional hazard model was used to calculate mortality hazard ratios and was
adjusted for age, sex, smoking duration in pack-years, hypertension, HDL/cholesterol ratio and diabetes
TABLE 1 Baseline characteristics of all subjects without peripheral arterial disease at
baseline, stratified by chronic obstructive pulmonary disease (COPD) status
Characteristic Overall No COPD COPD p-value#
Subjects 3123 (100) 3038 (97) 85 (3)
Age years 65.14±6.6 65.12±6.6 65.69±5.6 0.43
Female 1785 (57.2) 1745 (57.4) 40 (47.1) 0.07
BMI kg·m−2 26.27±3.5 26.28±3.5 26.17±3.1 0.78
Smoking status <0.01
Never 1069 (35.4) 1054 (35.8) 15 (18.5)
Former 1394 (46.1) 1348 (45.8) 46 (56.8)
Current 560 (18.5) 540 (18.4) 20 (24.7)
Ever smoking 1954 (64.6) 1888 (64.2) 66 (81.5) <0.01
Smoking duration pack-years¶ 25.5±21.3 25.3±21.2 33.5±24.1 <0.01
Diabetes mellitus 380 (12.6) 367 (12.5) 13 (15.9) 0.47
HDL/cholesterol ratio 0.21±0.1 0.21±0.1 0.22±0.1 0.13
Cholesterol lowering drugs 72 (2.3) 70 (2.3) 2 (2.4) 0.98
Hypertension 1481 (47.4) 1446 (47.6) 35 (41.2) 0.29
BP lowering drugs 770 (24.7) 743 (24.5) 27 (31.8) 0.12
hs-CRP 2.44±3.3 2.42±3.3 3.02±3.0 0.11
Inhaled therapy 124 (4.0) 64 (2.1) 60 (70.6) <0.01
Data are presented as n (%) or mean±SD. Data are original data without imputed values. In the total
population, missing values were present for smoking (3.2%), smoking duration in pack-years (7.1%), BMI
(0.2%) and diabetes mellitus (3.5%). BMI: body mass index; HDL: high-density lipoprotein; BP: blood
pressure; hs-CRP: high-sensitivity C-reactive protein. #: p-values represent the difference between COPD
groups; ¶: smoking duration in pack-years is presented for former and current smokers only.
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mellitus. We used SPSS version 21 (IBM Corp, Armonk, NY, USA) and R-software (The R Project for
Statistical computing; www.r-project.org) for all analyses.
Results
The characteristics of the population for follow-up (n=3123) are presented in table 1. The mean age±SD
was 65.1±6.6 years and 57.2% of subjects were women. The prevalence of ever smokers was 65% in the
total population and 67.1% in individuals with incident PAD (table 1 and table 2). Considering individuals
with PAD, almost all men (89.1%) and 48.3% of women were ever smokers. In total, 56 out of 3123
individuals (1.8%) had severe PAD based on an ABI of less than 0.6. Only 12 out of 56 subjects with
severe PAD (21.4%) indicated intermittent claudication on their questionnaire.
COPD and the association with newly diagnosed PAD
During a median follow-up of 7.4 years, 447 patients (12.9%) developed incident PAD. A statistically
significant association was found between COPD and newly diagnosed PAD during follow-up. The age-
and sex-adjusted odds ratio (OR) was 1.89 (95% CI 1.13–3.17) and 1.87 (95% CI 1.10–3.18) after
additional adjustment for smoking duration in pack-years, hypertension, HDL/cholesterol ratio and
diabetes mellitus (table 2). This association remained significant upon additional adjustment for baseline
hs-CRP levels (adjusted OR 1.86, 95% CI 1.10–3.16), exclusion of individuals (n=186) who developed
COPD during follow-up (adjusted OR 1.93, 95% CI 1.13–3.29) and upon exclusion of individuals (n=495)
with an ABI of greater than 1.40 (adjusted OR 1.95, 95% CI 1.13–3.36). The association between COPD
and incident PAD was stronger in males (adjusted OR 2.59, 95% CI 1.04–5.16) than females (adjusted OR
1.22, 95% CI 0.53–2.87). However, the test for interaction between COPD and sex was not significant
(p=0.18 for interaction). Stratified analysis by smoking status revealed that the overall association between
COPD and newly developed PAD was driven by the ever smoker group (p=0.41 for interaction) (table 2).
Disease status and risk of all-cause mortality
We investigated the impact of PAD on mortality by following all subjects from the time when the second
PAD measurement was performed (n=3123). The general characteristics of the population which was
followed-up for mortality are presented in table 3. The prevalence of PAD in COPD cases was 20.5%
(51 out of 249 individuals) while the prevalence of PAD in non-COPD cases was 13.8% (396 out of 2874
TABLE 2 The association between chronic obstructive pulmonary disease (COPD) and the
development of peripheral arterial disease (PAD), additionally stratified by sex and smoking
status
Stratification Subjects Model 1# Model 2¶ p-value+
Overall No PAD PAD OR (95% CI) OR (95% CI)
Overall 3123 (100) 2676 (100) 447 (100)
Non-COPD 3038 (97.3) 2611 (97.6) 427 (95.5) Ref
COPD 85 (2.7) 65 (2.4) 20 (5.0) 1.89 (1.13–3.18) 1.87 (1.10–3.18)
Sex 0.18
Male
Non-COPD 1293 (41.4) 1122 (41.9) 171 (38.3) Ref
COPD 45 (1.4) 32 (1.2) 13 (2.9) 2.61 (1.33–5.12) 2.59 (1.04–5.16)
Female
Non-COPD 1745 (55.9) 1489 (55.6) 256 (57.3) Ref
COPD 40 (1.3) 33 (1.2) 7 (1.6) 1.24 (0.54–2.87) 1.22 (0.53–2.87)
Smoking status 0.41
Never smoker
Non-COPD 1066 (34.1) 921 (34.4) 145 (32.4) Ref
COPD 15 (0.5) 13 (0.5) 2 (0.4) 1.00 (0.21–4.47) 1.20 (0.26–5.57)
Ever smoker
Non-COPD 1972 (63.1) 1690 (63.2) 282 (63.1) Ref
COPD 70 (2.2) 52 (1.9) 18 (4.0) 2.00 (1.14–3.50) 1.98 (1.12–3.49)
Data are presented as n (%) or ratio (95% CI). Data for smoking is represented by imputed values. Values
in bold are statistically significant. OR: odds ratio; Ref: reference value. #: model 1 is adjusted for age and
sex; ¶: model 2 is adjusted for age, sex, smoking duration in pack-years, hypertension, high-density
lipoprotein/cholesterol ratio and diabetes mellitus; +: p-value for interaction, calculated by adding an
interaction term to model 2.
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individuals). We stratified the study population into the following four groups: 1) no COPD or PAD
(n=2478), 2) COPD only (n=198), 3) PAD only (n=396), and 4) comorbid COPD and PAD (n=51).
Median follow-up time for mortality was 16.5 years. At the end of follow-up, 1805 individuals (58%) had
died. The mortality rate in the group without COPD and without PAD was 10.0 (95% CI 9.47–10.62) per
100000 person-years. Subjects with COPD only and subjects with PAD only had comparable mortality
rates of 18.4 (95% CI 15.49–21.58) and 16.1 (95% CI 14.17–18.16) per 100000 person-years, respectively.
In subjects with both COPD and PAD, the mortality rate was the highest at 30.1 (95% CI 22.01–40.11) per
100000 person-years. The Kaplan–Meier survival curves in the different groups are represented in figure 2.
Age- and sex-adjusted hazard ratios for mortality, as compared to individuals without COPD and without
PAD, were 1.41 (95% CI 1.24–1.61) for subjects with PAD only, 1.50 (95% CI 1.26–1.77) for subjects with
COPD only and 2.23 (95% CI 1.66–3.00) for subjects with both COPD and PAD. After additional
adjustment for smoking duration in pack-years, hypertension, HDL/cholesterol ratio and diabetes mellitus
the hazard ratios for mortality were 1.36 (95% CI 1.19–1.54) for subjects with PAD only, 1.52 (95% CI
1.28–1.80) for subjects with COPD only and 2.30 (95% CI 1.71–3.09) for subjects with both COPD and
PAD. We did not find effect modification by PAD on the multiplicative scale (p=0.82 for interaction). In
addition, sensitivity analysis after censoring for incident COPD during follow-up did not materially change
the results.
Discussion
To our knowledge, this is the first longitudinal population-based study that has investigated the association
between COPD and incident PAD, and the influence of PAD on mortality rates in individuals with
COPD. We observed that individuals with COPD have a higher risk of developing PAD and that the risk
of mortality was highest in people with both diseases.
Smoking is a well-known risk factor for both COPD and PAD. However, in our study, the association
between COPD and PAD remained statistically significant upon adjustment for cumulative smoking
TABLE 3 Baseline characteristics of all subjects followed for mortality at the second
peripheral arterial disease (PAD) assessment
Overall No COPD or PAD COPD only# PAD only COPD and PAD#
Subjects 3123 2478 198 396 51
Age years 71.73±6.58 71.13±6.36 72.79±5.95 74.58±7.21 74.84±6.89
Women 1785 (57.20) 1435 (57.90) 87 (43.90) 246 (62.10) 17 (33.30)
BMI kg·m−2 26.87±3.89 26.94±3.86 26.91±3.78 26.55±4.08 25.83±3.72
Ever smoker 2049 (65.60) 1580 (63.80) 163 (82.30) 261 (65.9) 45 (88.2)
Smoking duration pack-years¶ 25.47±22.50 23.99±22.01 34.13±26.62 26.49±19.85 39.78±25.63
Diabetes mellitus 816 (26.10) 608 (24.50) 63 (31.80) 130 (32.80) 15 (29.40)
HDL/cholesterol ratio 0.24±0.07 0.25±0.07 0.25±0.08 0.23±0.06 0.25±0.08
Data are presented as n (%) or mean±SD, and are represented by imputed values. Data are stratified as
subjects without chronic obstructive pulmonary disease (COPD) and without PAD, subjects with COPD only,
subjects with PAD only and subjects with both COPD and PAD. BMI: body mass index; HDL: high-density
lipoprotein. #: the total number of individuals with COPD at follow-up was 249 (COPD only (n=198) plus
COPD and PAD (n=51)). This represents those subjects with COPD at baseline (n=85; table 1) plus those
individuals that acquired COPD during follow-up. ¶: smoking duration in pack-years is presented for
former and current smokers only.
FIGURE 2 Kaplan–Meier curves of
mortality in different groups
according to the presence or
absence of chronic obstructive
pulmonary disease (COPD) and
peripheral arterial disease (PAD).
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history (in pack-years). Additionally, increased C-reactive protein (CRP) levels are known to be an
important risk factor for PAD and CRP is also elevated in a subgroup of patients with COPD [20].
However, adjusting for baseline hs-CRP levels did not change the overall association substantially. Despite
the potential for residual confounding or other unmeasured mediators of systemic inflammation, such as
tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) or matrix metalloproteinases, we hypothesise
that COPD-related mechanisms beyond smoking and systemic inflammation might contribute to the onset
of PAD.
COPD and PAD have a well-known impact on mortality, however, no study in the literature has
investigated the impact of PAD on the association between COPD and all-cause mortality. We observed a
higher risk of mortality in individuals when COPD and PAD co-occur, although there was no formal
statistical interaction between both diseases on a multiplicative scale. The observed mortality rates in
individuals with PAD or with COPD are in line with literature reports. The European Respiratory Society
(ERS) white book (www.erswhitebook.org) reported an age-standardised mortality rate for COPD of
approximately 18 per 100000 inhabitants per year (to the European Standard Population), while
unstandardized all-cause mortality in the subgroup of individuals with COPD only was 18.4 per 100000
person-years. In addition, in a group of patients with asymptomatic PAD, DIEHM et al. [21] reported a
mortality rate ratio of 1.4 after adjustment for known cardiovascular risk factors. We observed a similar
adjusted hazard ratio of 1.4 in our population, which highlights the robustness of our data.
Our findings have important implications for disease management [22]. As COPD is associated with PAD
development, with PAD often being asymptomatic, patients with COPD might benefit from routine ABI
screening for the timely diagnosis of PAD. Apart from its cost-effectiveness, early targeted screening and
treatment of asymptomatic PAD is likely to improve health by preventing future cardiovascular disease [23].
The strengths of this study are the prospective longitudinal design and the standardised data collection.
However, our study also has some limitations. First, information on PAD was only gathered at the study
centre, during study visits, implying that actual dates of PAD onset were missing and preventing us from
conducting a time-to-PAD development analysis. Secondly, since spirometry measurements were not
routinely performed in the early rounds of the Rotterdam Study, the incident date for COPD was based
solely on a clinical diagnosis of COPD and not all clinically diagnosed COPD subjects were still alive to be
confirmed by spirometry at the research centre at a later date. Thirdly, although we have evaluated all
available known potential confounders of the association between COPD and PAD development, residual
confounding might still explain part of this association. Finally, including patients with two ABI
measurements at two subsequent visits might lead to a selection towards healthier individuals.
Conclusion
Subjects with COPD have a higher risk of developing PAD. People with both COPD and PAD have a
substantially increased risk of death. Consequently, early detection of PAD and preventive actions in
people with COPD should receive more attention in clinical respiratory care.
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